FDA Week - 10/04/2019

Advocate Cites ‘Fearmongering’ In Biosimilars Space, ASBM Pushes Back

By Beth Wang / October 3, 2019 at 12:32 PM
A prominent Canadian patient advocate alleged a U.S.-based biologics industry group is engaging in “fearmongering” in her country as part of a bid to reduce confidence in biosimilars, but the targeted group, the Alliance for Safe Biologic Medicines, told Inside Health Policy it is merely raising legitimate concerns over Canada’s new policy that requires biosimilar switching without the involvement of physicians. An FDA official also said the agency has learned through focus groups that biased information could be leading...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.